News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Cipla Ltd. Joins Challengers To Sanofi-Synthelabo’s Plavix Drug
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cipla and its partner Watson Pharmaceuticals plan to seek US approval for a generic version of Sanofi-Synthelabo's blood-thinning drug Plavix, Cipla's chairman said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
FDA
Approvals
Regulatory
MORE ON THIS TOPIC
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
July 10, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
July 9, 2026
·
2 min read
·
Nick Paul Taylor
FDA
Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up
July 9, 2026
·
1 min read
·
Heather McKenzie
Neurodegenerative disease
GSK abandons Alector after back-to-back neuro stumbles
July 9, 2026
·
2 min read
·
Tristan Manalac
